Welcome to your Saturday Biotech & Pharma Stock Market Recap

What’s to be covered in this hallowed scroll:

1. Overview of the biotech & pharma stocks that had the best & worst weeks (as measured by % change in price)

2. We’ll give you a calendar of whose announcing earnings in the upcoming week - and if they’re before the markets open (BMO) or after markets close (AMC).

3. One more thing we’ll have in future weeks - a recap of the more notable earnings calls the week previous.

Lastly - all three of the above will have sub-sections divided by:

1. Biotechnology (life sciences and the like)

2. Drug Manufacturers - General (this one includes big pharma)

3. Drug Manufacturers - Specialty and Pharma (everyone else that makes drugs, and then some)

And last thing - everything is in USD unless otherwise stated!

This weekend edition is a new feature at TLDR Biotech, so I’d love to get your feedback.

(You can also reach out to me on LinkedIn)

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

Biotechnology

We gotta talk about Mustang Bio (MBIO) - their stock was up over 800%(!!!) intra-week before settling at a respectable +350%, after presenting positive news from one of their autologous CAR-T candidates.

For Seastar Medical (ICU), their stock has been making an ascent since June 13th, though not for a single reason - it could be due it being undervalued after it’s recent decline, recent board appointments, and/or more data being presented on it’s “cytopheretic” devices.

Aerovate Therapeutics (AVTE) stunning decline is due to a flopped Ph2b of what is, unfortunately, their sole product.

For Ovid Therapeutics (OVID), their decline is also due to disappointing Ph3 data, but it’s from an asset they sold to Takeda (TAK:NYSE), meaning Ovid won’t likely see any royalties.

Upcoming Biotechnology Earnings Calls

No earnings call next week for this group!

Instead, why not get mentally ready for Game 7 of the Stanley Cup Final on Monday?

AFFILIATE
Finviz: ✨Financial Visualizations🤩

I’m using Finviz to put together these compilations - it’s the easiest way to visualize and assess multiple stocks within the same industry (like within biotech).

If this is down your alley, you can check it out for free using my Affiliate link.

Drug Manufacturers - General

Scilex (SCLX) continues with week 2 on top of the leader board (they had a Ph3 win the week previous and the beginning of a commercial roll-out), but it’s not all rainbows - the intra-week chart shows they were up almost 50% at one point.

Gilead (GILD) is riding high on positive Ph3 data from their twice-yearly HIV prevention shot.

And though Amarin (AMRN) is facing a lawsuit, the decline this week looks to be a continuation from the past few months (and the reality of declining revenue).

Upcoming Drug Manufacturers - General Earnings Calls

No earnings next week for this week group!

Instead, why not learn about an unintended side effect of the GLP-1 craze - “Ozempic face”?

Drug Manufacturers - Specialty & Generic

For Harrow (HROW), a successful relaunch update for one of their commercial assets (and an analysts upgrade) sent the stock up this week.

Evoke Pharma (EVOK) surprising gap-up might be due to a light breeze - or someone wanted to make a cheeky bet on a friday afternoon (31% jump between 3:50pm and 4:00pm on June 21st).

Esperion’s (ESPR) stock was downgraded by the Bank of America, sending the ticker tumbling this week.

And lastly for Cardiol (CRDL), positive Ph2 results seems to have precipitated a retreat from YTD highs - though it might also be a market correction after a blistering 119% gain YTD.

Upcoming Drug Manufacturers - Specialty & Generic Earnings Calls

No earnings next week for this week group!

Instead, why not learn about Opiate abuse in the 19th century?

That’s all for now - go enjoy your weekend!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 500+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here